When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALDR - Alder BioPharmaceuticals: Too Speculative Too Many Competing Drugs In The Migraine Market
Alder BioPharmaceuticals Inc.
For the past couple years, Alder BioPharmaceuticals Inc. (ALDR) has been fighting a losing battle as an also-ran in a field dominated by giants of biopharma. The company has a drug called Eptinezumab targeting episodic as well as chronic migraines. Eptinezumab is a Calcitonin gene-related peptide inhibitor, or CGRP inhibitor, or CGRPi. There are 3 approved CGRPis in the market already, and uptake is very high. These drugs work pretty well, with very low side effects; so the question is, and always has been for Alder - why do we need another one?